

### **RNF11 Antibody (Center) Blocking peptide** Synthetic peptide

Catalog # BP12908c

## Specification

# **RNF11** Antibody (Center) Blocking peptide - Product Information

Primary Accession

<u>Q9Y3C5</u>

## **RNF11** Antibody (Center) Blocking peptide - Additional Information

Gene ID 26994

**Other Names** RING finger protein 11, RNF11

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **RNF11** Antibody (Center) Blocking peptide - Protein Information

Name RNF11

#### Function

Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of TNFAIP3 to RIPK1 after TNF stimulation. TNFAIP3 deubiquitinates 'Lys- 63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys- 48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Recruits STAMBP to the E3 ubiquitin-ligase SMURF2 for ubiquitination, leading to its degradation by the 26S proteasome.

### **Cellular Location**

Early endosome. Recycling endosome. Cytoplasm. Nucleus. Note=Predominantly cytoplasmic, when unphosphorylated, and nuclear, when phosphorylated by PKB/AKT1

#### Tissue Location

Expressed at low levels in the lung, liver, kidney, pancreas, spleen, prostate, thymus, ovary, small intestine, colon, and peripheral blood lymphocytes, and, at intermediate levels, in the testis, heart, brain and placenta. Highest expression in the skeletal muscle. In the brain, expressed at different levels in several regions: high levels in the amygdala, moderate in the hippocampus and thalamus, low in the caudate and extremely low levels in the corpus callosum (at protein level). Restricted to



neurons, enriched in somatodendritic compartments and excluded from white matter (at protein level). In substantia nigra, present in cell bodies and processes of dopaminergic and nondopaminergic cells (at protein level). In Parkinson disease, sequestered in Lewy bodies and neurites. Overexpressed in breast cancer cells, but not detected in the surrounding stroma and weakly, if at all, in normal breast epithelial cells (at protein level). Also expressed in several tumor cell lines.

## **RNF11 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

#### <u>Blocking Peptides</u>

## RNF11 Antibody (Center) Blocking peptide - Images

### **RNF11 Antibody (Center) Blocking peptide - Background**

The protein encoded by this gene contains a RING-H2 fingermotif, which is known to be important for protein-proteininteractions. The expression of this gene has been shown to beinduced by mutant RET proteins (MEN2A/MEN2B). The germlinemutations in RET gene are known to be responsible for thedevelopment of multiple endocrine neoplasia (MEN). [provided byRefSeq].

### **RNF11 Antibody (Center) Blocking peptide - References**

Santonico, E., et al. Oncogene 29(41):5604-5618(2010)Markson, G., et al. Genome Res. 19(10):1905-1911(2009)Shembade, N., et al. EMBO J. 28(5):513-522(2009)van Wijk, S.J., et al. Mol. Syst. Biol. 5, 295 (2009) :Chen, C., et al. Oncogene 27(54):6845-6855(2008)